Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pdl Biopharma Inc (PDLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 378,303
  • Shares Outstanding, K 160,980
  • Annual Sales, $ 244,300 K
  • Annual Income, $ 63,610 K
  • 36-Month Beta 0.49
  • Price/Sales 1.55
  • Price/Cash Flow 5.67
  • Price/Book 0.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.11 +10.66%
on 05/04/17
2.44 -4.30%
on 05/10/17
+0.17 (+8.10%)
since 04/24/17
3-Month
1.96 +19.13%
on 03/24/17
2.44 -4.30%
on 05/10/17
+0.12 (+5.18%)
since 02/24/17
52-Week
1.93 +20.98%
on 12/20/16
3.77 -38.06%
on 11/15/16
-0.87 (-27.03%)
since 05/24/16

Most Recent Stories

More News
LENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR

Debt-to-Equity Conversion Plan with PDL BioPharma, Inc., Strengthens Company's Balance Sheet to Support Leadership Position in Refractive Cataract Surgery

PDLI : 2.33 (-0.85%)
LENSAR(R) Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam(R) Tomographers

LENSAR, Inc., a global leader in next generation femtosecond laser technology for refractive cataract surgery, today announced it received 510(k) clearance for integration of the popular...

PDLI : 2.33 (-0.85%)
PDL BioPharma Announces First Quarter 2017 Financial Results

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2017 including:

PDLI : 2.33 (-0.85%)
PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2017 financial results for the period ended March 31, 2017, on Wednesday, May 3,...

PDLI : 2.33 (-0.85%)
PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that on April 21, 2017, the Company entered into a settlement agreement with certain subsidiaries of Merck & Co., Inc. ("Merck")...

PDLI : 2.33 (-0.85%)
MRK : 64.94 (+0.60%)
Biotech Stocks on Investors' Radar -- Halozyme Therapeutics, Cara Therapeutics, PDL BioPharma, and Arena Pharma

On Wednesday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 0.52%; the Dow Jones Industrial Average edged 0.29% lower; and the S&P 500 was down 0.38%....

CARA : 17.09 (-0.35%)
PDLI : 2.33 (-0.85%)
ARNA : 1.38 (+1.47%)
HALO : 12.80 (+0.39%)
PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Friday, June 9, 2017, at 10:00 a.m. Pacific Time for all stockholders...

PDLI : 2.33 (-0.85%)
Clinical Trial Advancements With Positive Data for Phase 1 and 2 Results Fueling Steady Growth in Biomedical Industry

PALM BEACH, Florida, April 4, 2017 /PRNewswire/ --

RP.VN : 0.750 (-5.06%)
WMGI : 27.18 (-0.77%)
NVCR : 13.25 (+14.22%)
PDLI : 2.33 (-0.85%)
REPCF : 0.5756 (-1.10%)
COOL : 17.11 (+12.27%)
Clinical Trial Advancements With Positive Data for Phase 1 and 2 Results Fueling Steady Growth in Biomedical Industry

MarketNewsUpdates.com News Commentary

RP.VN : 0.750 (-5.06%)
WMGI : 27.18 (-0.77%)
NVCR : 13.25 (+14.22%)
REPCF : 0.5756 (-1.10%)
PDLI : 2.33 (-0.85%)
COOL : 17.11 (+12.27%)
WMGIZ : 1.41 (+0.71%)
PDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It Continue?

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PDLI : 2.33 (-0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Business Summary

Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital...

See More

Support & Resistance

2nd Resistance Point 2.45
1st Resistance Point 2.40
Last Price 2.33
1st Support Level 2.32
2nd Support Level 2.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.